6 days Ago By ABMN Staff
Alliancebernstein L.P. lifted its holdings in shares of Rhythm Pharmaceuticals, Inc.
( NASDAQ:RYTM – Free Report ) by 3.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 61,470 shares of the company’s stock after buying an additional 1,900 shares during the period.
Alliancebernstein L.P. owned approximately 0.
10% of Rhythm Pharmaceuticals worth $3,441,000 at the end of the most recent reporting period. A number of other institutional investors and hedge funds have also added to or reduced their stakes in RYTM. Barclays PLC grew its stake in shares of Rhythm Pharmaceuticals by 79.
6% in the third quarter. Barclays PLC now owns 106,397 shares of the company’s stock worth $5,574,000 after purchasing an additional 47,166 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Rhythm Pharmaceuticals by 0.
3% during the 3rd quarter. Geode Capital Management LLC now owns 1,256,188 shares of the company’s stock worth $65,824,000 after buying an additional 3,499 shares in the last quarter. Franklin Resources Inc.
lifted its stake in shares of Rhythm Pharmaceuticals by 11.5% in the 3rd quarter. Franklin Resources Inc.
now owns 259,416 shares of the company’s stock worth $13,033,000 after acquiring an additional 26,739 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Rhythm Pharmaceuticals by 241.
9% in the third quarter. Principal Financial Group Inc. now owns 32,586 shares of the company’s stock valued at $1,707,000 after acquiring an additional 23,054 shares in the last quarter.
Finally, Raleigh Capital Management Inc. bought a new stake in Rhythm Pharmaceuticals during the fourth quarter worth approximately $28,000. Rhythm Pharmaceuticals Price Performance NASDAQ RYTM opened at $60.
14 on Tuesday. The company has a 50 day simple moving average of $54.55 and a 200-day simple moving average of $55.
43. Rhythm Pharmaceuticals, Inc. has a 52-week low of $35.
17 and a 52-week high of $68.58. The firm has a market capitalization of $3.
80 billion, a price-to-earnings ratio of -13.89 and a beta of 2.32.
Wall Street Analyst Weigh In Several brokerages have recently weighed in on RYTM. Wells Fargo & Company upped their price objective on Rhythm Pharmaceuticals from $80.00 to $91.
00 and gave the company an “overweight” rating in a report on Monday, April 7th. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price (up from $70.
00) on shares of Rhythm Pharmaceuticals in a report on Tuesday, April 8th. JMP Securities restated a “market outperform” rating and set a $75.00 target price on shares of Rhythm Pharmaceuticals in a report on Monday, December 23rd.
Jefferies Financial Group started coverage on Rhythm Pharmaceuticals in a report on Thursday, January 2nd. They issued a “buy” rating and a $80.00 price target on the stock.
Finally, Bank of America upgraded Rhythm Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $63.00 target price on the stock in a report on Monday, April 7th. Thirteen analysts have rated the stock with a buy rating, According to MarketBeat.
com, the stock presently has an average rating of “Buy” and a consensus target price of $74.92. Read Our Latest Stock Analysis on RYTM Insider Buying and Selling at Rhythm Pharmaceuticals In related news, EVP Yann Mazabraud sold 75,000 shares of the business’s stock in a transaction that occurred on Friday, March 14th.
The stock was sold at an average price of $51.48, for a total value of $3,861,000.00.
Following the completion of the sale, the executive vice president now owns 40,370 shares of the company’s stock, valued at approximately $2,078,247.60. The trade was a 65.
01 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link . Also, insider Pamela J.
Cramer sold 20,760 shares of the stock in a transaction that occurred on Tuesday, April 8th. The stock was sold at an average price of $60.14, for a total value of $1,248,506.
40. Following the completion of the transaction, the insider now owns 19,209 shares in the company, valued at $1,155,229.26.
This represents a 51.94 % decrease in their position. The disclosure for this sale can be found here .
Insiders have sold 146,641 shares of company stock worth $8,112,177 over the last 90 days. 5.60% of the stock is currently owned by corporate insiders.
About Rhythm Pharmaceuticals ( Free Report ) Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. Featured Stories Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
